Tebentafusp: a first-in-class treatment for metastatic uveal melanoma
Tebentafusp is a first-in-class immunotherapy agent that comprises an engineered T-cell receptor targeting a gp100 epitope presented by human leukocyte antigen-A*02:01 cells, fused to an anti-CD3 single-chain variable fragment. Tebentafusp is both the first bispecific T-cell engager to show efficacy...
Сохранить в:
| Главные авторы: | , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
SAGE Publishing
2023-03-01
|
| Серии: | Therapeutic Advances in Medical Oncology |
| Online-ссылка: | https://doi.org/10.1177/17588359231160140 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|